FCCC LOGO Faculty Publications
Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers
Am J Surg. 2021 May 23
PMID: 34045068   
Back to previous list
Abstract
BACKGROUND: Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. METHODS: The National Cancer Database from 2004 to 2016 was used. RESULTS: 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR: 4.27 and 2.42; p < 0.0001 and 0.009) compared to community centers. Patients with stage III non-SRGC (NSRGC) had a 2.4 times higher odds of receiving NAT at academic centers. The R1 resection rate for NSRGC was lower at academic centers (OR: 0.67; p = 0.0018). Lymph node harvest ≥15 nodes was 1.6 and 1.9 times higher at academic centers for NSRGC and SRGC, respectively. Patients treated at academic centers had a significantly improved overall survival (OS). CONCLUSIONS: Treatment at academic centers is associated with significant improvements in oncologic metrics and OS.
Notes
1879-1883 Moslim, Maitham A Deng, Mengying Handorf, Elizabeth Greco, Stephanie H Farma, Jeffrey M Journal Article United States Am J Surg. 2021 May 23:S0002-9610(21)00287-7. doi: 10.1016/j.amjsurg.2021.05.007.